" class="no-js "lang="en-US"> Orexo Archives - Medtech Alert
Friday, March 29, 2024

Sort by:

Date

Top Post

Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease

An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]

Orexo Shares New Timeline for the High-Dose Rescue Medication for Opioid Overdose, OX124

Orexo today announces the expected US launch of OX124, a high-dose rescue medication for opioid overdose, […]

Orexo Submits New Drug Application to FDA for OX124, a High-dose Rescue Medication for Opioid Overdose

Orexo AB announces the submission of a New Drug Application (NDA) to the US Food and […]

Orexo’s Nasal Adrenaline Rescue Medication OX640 Enters Clinical Development

Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY) today announces it has successfully initiated the first explorative human clinical study […]

Orexo Appoints Fredrik Järrsten as New CFO

Orexo AB (publ.), (STO:ORX) (OTCQX:ORXOY), announces today that the company has appointed Fredrik Järrsten as […]

Orexo Provides Information About its New Proprietary Drug Delivery Platform - AmorphOXTM

Orexo AB (publ.),(STO:ORX) (OTCQX:ORXOY) today provides information about its new proprietary drug delivery platform, amorphOXTM, a […]

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more